Anzeige
Erschienen in:
01.04.2012 | Original Paper
Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer
Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2012
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Peroxiredoxins, which reduced intracellular peroxides as a noval kind of antioxidant protein, were extensively expressed in various types of cancers and were thought as a biomarker of cancer cells. In this work, we performed genotyping analyses for tag SNP of Prdx 1, 2 and 6, and then evaluated the association with susceptibility and clinic stage of esophageal squamous cell carcinoma (ESCC) in a case–control study.
Methods
The protein level of these Prdx isoforms in ESCC cancer samples was evaluated by Western blot. Then 356 ESCC cancer cases and 315 controls were genotyped by SNPshot assay. Differences in frequencies of the genotypes of the SNPs variant between the cases and controls were evaluated by using the chi-square test.
Results
Our result of Western blot confirmed the aberrant expression of Prdx 1, 2 and 6 in ESCC samples, which was coincident with other studies. After genotyping by SNPshot assay, the result showed that the allele and genotype frequencies did not differ between the patients and controls. And no association between the polymorphism and the progression of ESCC including tumor grade and stage was found.
Conclusions
Our data suggested that polymorphisms of Prdx 1, 2 and 6 were not associated with esophageal cancer.